Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).

Robert J. Motzer,Toni K. Choueiri,Jessica May,YoungMin Kwon,Nifasha Rusibamayila,Marc F. Botteman,Melissa Hamilton,Flavia Ejzykowicz,David Cella

Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).

2021

Robert J. Motzer
Toni K. Choueiri
Jessica May
YoungMin Kwon
Nifasha Rusibamayila
Marc F. Botteman
Melissa Hamilton
Flavia Ejzykowicz
David Cella

6568Background: After a minimum follow-up of 48 months (mos), the CheckMate 214 trial (phase 3, NCT02231749) continued to demonstrate a significant overall (OS) and progression-free (PFS) survival ...

Keywords:

Renal cell carcinoma
Ipilimumab
Internal medicine
Oncology
Nivolumab
Medicine
first line treatment
Sunitinib
long term trend

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations